Modifying the Disease Course
The interferon beta medications (Avonex®, Betaseron®, Extavia®, Plegridy® and Rebif®), Aubagio® (teriflunomide), Gilenya® (fingolimod), Lemtrada™ (alemtuzumab),Tecfidera® (dimethyl fumarate), and Tysabri® (natalizumab) are all approved by the FDA for use in relapsing forms of MS, which include those individuals who have transitioned to secondary-progressive MS but continue to have relapses and/or evidence of disease activity on MRI. Therefore, a person who has been on one of these medications during the initial relapsing-remitting phase of the disease will likely continue on it unless his or her physician feels that it is no longer doing an adequate job of controlling disease activity. At that time, the physician will likely recommend changing to another one of these medications or to Novantrone® (mitoxantrone), a chemotherapeutic agent that has been approved by the FDA specifically for SPMS, as well as worsening relapsing MS.
Read more in The MS Disease-Modifying Medications (.pdf).